EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Insulet's enterprise value is $12,246 Mil.
Insulet's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,697 Mil. Therefore, Insulet's EV-to-Revenue for today is 7.22.
The historical rank and industry rank for Insulet's EV-to-Revenue or its related term are showing as below:
PODD'
s EV-to-Revenue Range Over the Past 10 Years
Min: 5.39 Med: 10.27 Max: 21.63
Current: 7.22
During the past 13 years, the highest EV-to-Revenue of Insulet was 21.63. The lowest was 5.39. And the median was 10.27.
PODD's EV-to-Revenue is ranked worse than 76.88% of 826
companies
in the Medical Devices & Instruments industry
Industry Median: 2.925
vs PODD: 7.22
As of today (2024-04-19), Insulet's stock price is $163.555.
Insulet's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $22.69. Therefore, Insulet's PS Ratio for today is 7.21.
Insulet EV-to-Revenue Historical Data
The historical data trend for Insulet's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Insulet Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
15.23
18.78
17.19
16.23
9.36
Insulet Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
16.23
16.82
14.25
7.63
9.36
Competitive Comparison
For the Medical Devices subindustry, Insulet's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet EV-to-Revenue Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Insulet's EV-to-Revenue falls into.
Insulet's current Enterprise Value is $12,246 Mil.
Insulet's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,697 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet's share price for today is $163.555.
Insulet's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Insulet's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PODD has been successfully added to your 